-
1
-
-
0022868893
-
Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon
-
1:STN:280:DyaL2s%2FmsV2gsw%3D%3D 10.1056/NEJM198612183152503 3097544
-
JH Hoofnagle KD Mullen BD Jones, et al. 1986 Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon N Engl J Med 315 1575 1578 1:STN:280:DyaL2s%2FmsV2gsw%3D%3D 10.1056/NEJM198612183152503 3097544
-
(1986)
N Engl J Med
, vol.315
, pp. 1575-1578
-
-
Hoofnagle, J.H.1
Mullen, K.D.2
Jones, B.D.3
-
2
-
-
0024509701
-
Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome
-
1:CAS:528:DyaL1MXit1Khtrk%3D 10.1126/science.2523562 2523562
-
QL Choo G Kuo AJ Weiner, et al. 1989 Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome Science 244 359 362 1:CAS:528:DyaL1MXit1Khtrk%3D 10.1126/science.2523562 2523562
-
(1989)
Science
, vol.244
, pp. 359-362
-
-
Choo, Q.L.1
Kuo, G.2
Weiner, A.J.3
-
3
-
-
0032547938
-
Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
-
DOI 10.1056/NEJM199811193392101
-
JG McHutchison SC Gordon ER Schiff, et al. 1998 Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group N Engl J Med 339 1485 1492 1:CAS:528:DyaK1cXnslGmtbs%3D 10.1056/NEJM199811193392101 9819446 (Pubitemid 28543496)
-
(1998)
New England Journal of Medicine
, vol.339
, Issue.21
, pp. 1485-1492
-
-
Mchutchison, J.G.1
Gordon, S.C.2
Schiff, E.R.3
Shiffman, M.L.4
Lee, W.M.5
Rustgi, V.K.6
Goodman, Z.D.7
Ling, M.-H.8
Cort, S.9
Albrecht, J.K.10
-
4
-
-
0035934568
-
Peginterferon alfa-2b plus ribavirin compared with interferonalfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial
-
DOI 10.1016/S0140-6736(01)06102-5
-
MP Manns JG McHutchison SC Gordon, et al. 2001 Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial Lancet 358 958 965 1:CAS:528:DC%2BD3MXntF2qtb8%3D 10.1016/S0140-6736(01)06102-5 11583749 (Pubitemid 32913521)
-
(2001)
Lancet
, vol.358
, Issue.9286
, pp. 958-965
-
-
Manns, M.P.1
McHutchison, J.G.2
Gordon, S.C.3
Rustgi, V.K.4
Shiffman, M.5
Reindollar, R.6
Goodman, Z.D.7
Koury, K.8
Ling, M.-H.9
Albrecht, J.K.10
-
5
-
-
0037179698
-
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection
-
1:CAS:528:DC%2BD38Xnt12rtb0%3D 10.1056/NEJMoa020047 12324553
-
MW Fried ML Shiffman KR Reddy, et al. 2002 Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 975 982 1:CAS:528:DC%2BD38Xnt12rtb0%3D 10.1056/NEJMoa020047 12324553
-
(2002)
N Engl J Med
, vol.347
, pp. 975-982
-
-
Fried, M.W.1
Shiffman, M.L.2
Reddy, K.R.3
-
6
-
-
79551505543
-
Genetic organization and diversity of the hepatitis C virus
-
QL Choo KH Richman JH Han, et al. 1994 Genetic organization and diversity of the hepatitis C virus Virol 68 4420 4426
-
(1994)
Virol
, vol.68
, pp. 4420-4426
-
-
Choo, Q.L.1
Richman, K.H.2
Han, J.H.3
-
7
-
-
68249154875
-
Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection
-
1:CAS:528:DC%2BD1MXps1Kjuro%3D 10.1056/NEJMoa0808010 19625712
-
JG McHutchison EJ Lawitz ML Shiffman, et al. 2009 Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection N Engl J Med 361 580 593 1:CAS:528:DC%2BD1MXps1Kjuro%3D 10.1056/NEJMoa0808010 19625712
-
(2009)
N Engl J Med
, vol.361
, pp. 580-593
-
-
McHutchison, J.G.1
Lawitz, E.J.2
Shiffman, M.L.3
-
8
-
-
0024238272
-
Synthetic peptides as substrates and inhibitors of human immune deficiency virus-1 protease
-
1:CAS:528:DyaL1MXitVemtg%3D%3D 3056930
-
S Billich MT Knoop J Hansen, et al. 1988 Synthetic peptides as substrates and inhibitors of human immune deficiency virus-1 protease J Biol Chem 263 17905 17908 1:CAS:528:DyaL1MXitVemtg%3D%3D 3056930
-
(1988)
J Biol Chem
, vol.263
, pp. 17905-17908
-
-
Billich, S.1
Knoop, M.T.2
Hansen, J.3
-
9
-
-
7644232426
-
Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients
-
DOI 10.1053/j.gastro.2004.08.002, PII S0016508504013915
-
H Hinrichsen Y Benhamou H Wedemeyer, et al. 2004 Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients Gastroenterology 127 1347 1355 1:CAS:528:DC%2BD2cXhtVKisrzI 10.1053/j.gastro.2004.08.002 15521004 (Pubitemid 39457761)
-
(2004)
Gastroenterology
, vol.127
, Issue.5
, pp. 1347-1355
-
-
Hinrichsen, H.1
Benhamou, Y.2
Wedemeyer, H.3
Reiser, M.4
Sentjens, R.E.5
Calleja, J.L.6
Forns, X.7
Erhardt, A.8
Cronlein, J.9
Chaves, R.L.10
Yong, C.-L.11
Nehmiz, G.12
Steinmann, G.G.13
-
10
-
-
59149103099
-
Protease and polymerase inhibitors for the treatment of hepatitis C
-
10.1111/j.1478-3231.2008.01928.x 19207967
-
T Asselah Y Benhamou P Marcellin 2009 Protease and polymerase inhibitors for the treatment of hepatitis C Liver Int 29 Suppl 1 57 67 10.1111/j.1478-3231. 2008.01928.x 19207967
-
(2009)
Liver Int
, vol.29
, Issue.SUPPL. 1
, pp. 57-67
-
-
Asselah, T.1
Benhamou, Y.2
Marcellin, P.3
-
11
-
-
77956268467
-
Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT 1): An open-label, randomised, multicentre phase 2 trial
-
1:CAS:528:DC%2BC3cXhtVymt7zP 10.1016/S0140-6736(10)60934-8 20692693
-
PY Kwo EJ Lawitz J McCone, et al. 2010 Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT 1): an open-label, randomised, multicentre phase 2 trial Lancet 376 705 716 1:CAS:528:DC%2BC3cXhtVymt7zP 10.1016/S0140-6736(10)60934-8 20692693
-
(2010)
Lancet
, vol.376
, pp. 705-716
-
-
Kwo, P.Y.1
Lawitz, E.J.2
McCone, J.3
-
13
-
-
28844451934
-
Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia
-
DOI 10.1016/j.jhep.2005.10.003, PII S0168827805006677
-
S Zeuzem M Buti P Ferenci, et al. 2006 Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia J Hepatol 44 97 103 1:CAS:528:DC%2BD2MXht12ktLjL 10.1016/j.jhep.2005.10.003 16290907 (Pubitemid 41772522)
-
(2006)
Journal of Hepatology
, vol.44
, Issue.1
, pp. 97-103
-
-
Zeuzem, S.1
Buti, M.2
Ferenci, P.3
Sperl, J.4
Horsmans, Y.5
Cianciara, J.6
Ibranyi, E.7
Weiland, O.8
Noviello, S.9
Brass, C.10
Albrecht, J.11
-
14
-
-
33646590308
-
Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon -2a (40 kd)/ribavirin therapy
-
DOI 10.1002/hep.21159
-
DM Jensen TR Morgan P Marcellin, et al. 2006 Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy Hepatology 43 954 960 1:CAS:528:DC%2BD28XkvFGmt7o%3D 10.1002/hep.21159 16628671 (Pubitemid 43724620)
-
(2006)
Hepatology
, vol.43
, Issue.5
, pp. 954-960
-
-
Jensen, D.M.1
Morgan, T.R.2
Marcellin, P.3
Pockros, P.J.4
Reddy, K.R.5
Hadziyannis, S.J.6
Ferenci, P.7
Ackrill, A.M.8
Willems, B.9
-
15
-
-
23444460553
-
Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin
-
DOI 10.1016/j.jhep.2005.04.009, PII S016882780500320X
-
P Ferenci MW Fried ML Shiffman, et al. 2005 Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin J Hepatol 43 425 433 1:CAS:528:DC%2BD2MXntVCkurY%3D 10.1016/j.jhep.2005.04.009 15990196 (Pubitemid 41111423)
-
(2005)
Journal of Hepatology
, vol.43
, Issue.3
, pp. 425-433
-
-
Ferenci, P.1
Fried, M.W.2
Shiffman, M.L.3
Smith, C.I.4
Marinos, G.5
Goncales Jr., F.L.6
Haussinger, D.7
Diago, M.8
Carosi, G.9
Dhumeaux, D.10
Craxi, A.11
Chaneac, M.12
Reddy, K.R.13
-
19
-
-
65449152185
-
Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection
-
1:CAS:528:DC%2BD1MXlsVGmtrc%3D 10.1056/NEJMoa0806104 19403902
-
JG McHutchison GT Everson SC Gordon, et al. 2009 Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection N Engl J Med 360 1827 1838 1:CAS:528:DC%2BD1MXlsVGmtrc%3D 10.1056/NEJMoa0806104 19403902
-
(2009)
N Engl J Med
, vol.360
, pp. 1827-1838
-
-
McHutchison, J.G.1
Everson, G.T.2
Gordon, S.C.3
-
20
-
-
77953416889
-
Review: New direct-acting antivirals in the development for hepatitis C virus infection
-
1:CAS:528:DC%2BC3cXhs1akur%2FO 10.1177/1756283X10363055
-
P Pockros 2010 Review: New direct-acting antivirals in the development for hepatitis C virus infection Therapeutic Adv Gastroenterol 3 191 202 1:CAS:528:DC%2BC3cXhs1akur%2FO 10.1177/1756283X10363055
-
(2010)
Therapeutic Adv Gastroenterol
, vol.3
, pp. 191-202
-
-
Pockros, P.1
-
21
-
-
78049460599
-
HCV treatment-related anemia is associated with higher sustained virologic response rate
-
• (Epub ahead of print). This article provides a clinical description of the correlation of anemia and sustained virologic response. Anemia is not always a bad thing
-
• Sulkowski MS, Shiffman ML, Afdhal NH, et al.: HCV treatment-related anemia is associated with higher sustained virologic response rate. Gastroenterology 2010 (Epub ahead of print). This article provides a clinical description of the correlation of anemia and sustained virologic response. Anemia is not always a bad thing.
-
(2010)
Gastroenterology
-
-
Sulkowski, M.S.1
Shiffman, M.L.2
Afdhal, N.H.3
-
22
-
-
77949773445
-
ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C
-
1:CAS:528:DC%2BC3cXit1SmtLo%3D 10.1038/nature08825 20173735 This important paper outlines a gene variant responsible for protecting against ribavirin-induced anemia
-
J Fellay AJ Thompson D Ge, et al. 2010 ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C Nature 464 405 408 1:CAS:528:DC%2BC3cXit1SmtLo%3D 10.1038/nature08825 20173735 This important paper outlines a gene variant responsible for protecting against ribavirin-induced anemia
-
(2010)
Nature
, vol.464
, pp. 405-408
-
-
Fellay, J.1
Thompson, A.J.2
Ge, D.3
-
23
-
-
77953881002
-
Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus
-
1:CAS:528:DC%2BC3cXpsFait7s%3D 10.1053/j.gastro.2010.04.013 20399780 This landmark clinical paper describes the power of the IL-28B polymorphism and its effect on interferon response between ethnicities. Much of the lower response in black patients is explained by this finding
-
AJ Thompson AJ Muir MS Sulkowski, et al. 2010 Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus Gastroenterology 139 120 129 1:CAS:528:DC%2BC3cXpsFait7s%3D 10.1053/j.gastro. 2010.04.013 20399780 This landmark clinical paper describes the power of the IL-28B polymorphism and its effect on interferon response between ethnicities. Much of the lower response in black patients is explained by this finding
-
(2010)
Gastroenterology
, vol.139
, pp. 120-129
-
-
Thompson, A.J.1
Muir, A.J.2
Sulkowski, M.S.3
|